Published in Ned Tijdschr Geneeskd on April 12, 1986
Nomogram for derivation of renal threshold phosphate concentration. Lancet (1975) 3.20
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J (1980) 2.29
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner (1986) 2.23
Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 2.02
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet (1983) 2.00
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet (1987) 1.90
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 1.78
Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet (1968) 1.77
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer (1985) 1.74
Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int (1980) 1.65
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun (1989) 1.64
Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J Biol Chem (2001) 1.62
Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop Relat Res (1987) 1.55
Molecular pharmacological aspects of histamine receptors. Pharmacol Ther (1995) 1.47
The assessment of phosphate reabsorption. Clin Chim Acta (1969) 1.42
Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost (2003) 1.41
The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H(2) receptor. Mol Pharmacol (2000) 1.41
Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits. Menopause (2001) 1.40
[Consensus conference on osteoporosis]. Ned Tijdschr Geneeskd (1986) 1.39
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) (1987) 1.33
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner (1987) 1.31
Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol (2001) 1.29
Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res (1988) 1.22
Natriuretic effect of calcitonin in man. N Engl J Med (1971) 1.21
Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from Pasteurella multocida, and purified dermonecrotic toxin from P. multocida. Infect Immun (1987) 1.19
APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum (1980) 1.18
Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner (1989) 1.15
Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol (2001) 1.13
Adenylyl cyclase 6 is selectively regulated by protein kinase A phosphorylation in a region involved in Galphas stimulation. Proc Natl Acad Sci U S A (1997) 1.13
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med (1987) 1.13
Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab (1985) 1.12
Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res (2010) 1.08
Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int (1990) 1.06
Paget's bone disease treated with diphosphonate and calcitonin. Lancet (1976) 1.05
Agonist-independent regulation of constitutively active G-protein-coupled receptors. Trends Biochem Sci (1998) 1.05
Sensitive liquid chromatography-tandem mass spectrometry method for the determination of clarithromycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.03
Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci (1969) 1.02
Expression of Q227L-galphas in MCF-7 human breast cancer cells inhibits tumorigenesis. Proc Natl Acad Sci U S A (1998) 1.01
Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet (1986) 1.00
Bone scintigraphy and radiology in Paget's disease of bone: a review. Am J Physiol Imaging (1988) 0.99
Modulation of forskolin-mediated adenylyl cyclase activation by constitutively active G(S)-coupled receptors. FEBS Lett (1997) 0.98
Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest (1982) 0.98
Homologous histamine H1 receptor desensitization results in reduction of H1 receptor agonist efficacy. Eur J Pharmacol (1991) 0.98
Effects of histamine H1-, H2- and H3-receptor selective drugs on the mechanical activity of guinea-pig small and large intestine. Br J Pharmacol (1991) 0.97
Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. J Biol Chem (1999) 0.95
Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner (1986) 0.94
Relation between signs and symptoms in Paget's disease of bone. Q J Med (1986) 0.93
Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet (1984) 0.93
A simple slide-rule method for the assessment of renal tubular reaborption of phosphate in man. Clin Chim Acta (1977) 0.93
Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone. Eur J Clin Invest (1982) 0.92
Renal phosphate excretion in man. Folia Med Neerl (1972) 0.92
Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptors. Br J Pharmacol (2008) 0.91
Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment. J Clin Endocrinol Metab (1987) 0.91
Familial benign hypercalcaemia. Study of a large family. Q J Med (1983) 0.91
Primary oxalosis: clinical and biochemical response to high-dose pyridoxine therapy. Metabolism (1979) 0.91
Effect of a diphosphonate on para-articular ossification after total hip replacement. Acta Orthop Scand (1974) 0.90
Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br J Pharmacol (2013) 0.90
Different profiles of desensitization dynamics in guinea-pig jejunal longitudinal smooth muscle after stimulation with histamine and methacholine. Br J Pharmacol (1990) 0.89
The use of bisphosphonates in the treatment of osteoporosis. Bone (1992) 0.89
A viral conspiracy: hijacking the chemokine system through virally encoded pirated chemokine receptors. Curr Top Microbiol Immunol (2006) 0.89
Differential effects of eicosapentaenoic acid on glycerolipid and apolipoprotein B metabolism in primary human hepatocytes compared to HepG2 cells and primary rat hepatocytes. Biochim Biophys Acta (1995) 0.89
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol (1986) 0.88
Results of prolonged treatment of Paget's disease of bone with disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Neth J Med (1974) 0.88
Pharmacological characterization of the human histamine H2 receptor stably expressed in Chinese hamster ovary cells. Br J Pharmacol (1994) 0.88
Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol (1986) 0.87
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium. Calcif Tissue Int (1982) 0.87
Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int (1988) 0.87
Modelling and mutation studies on the histamine H1-receptor agonist binding site reveal different binding modes for H1-agonists: Asp116 (TM3) has a constitutive role in receptor stimulation. J Comput Aided Mol Des (1995) 0.86
Radiological demonstration of healing in Paget's disease of bone treated with APD. Br J Radiol (1985) 0.86
Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer (1987) 0.86
Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3. Br J Pharmacol (2012) 0.85
The role of cytomegalovirus-encoded homologs of G protein-coupled receptors and chemokines in manipulation of and evasion from the immune system. J Clin Virol (2001) 0.85
Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem (1998) 0.85
Untreated Paget disease of bone studied by scintigraphy. Radiology (1984) 0.85
Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity. J Thromb Haemost (2003) 0.85
Inorganic pyrophosphatase in mineralizing hamster molars. 3. Influence of diphosphonates. Calcif Tissue Res (1973) 0.84
Relationship of inorganic pyrophosphatase and alkaline phosphatase activities in hamster molars. Calcif Tissue Res (1970) 0.84
Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res (1989) 0.84
Lysine200 located in the fifth transmembrane domain of the histamine H1 receptor interacts with histamine but not with all H1 agonists. Biochem Biophys Res Commun (1995) 0.84
Differences in propionate-induced inhibition of cholesterol and triacylglycerol synthesis between human and rat hepatocytes in primary culture. Br J Nutr (1995) 0.84
Sensitization of the histamine H1 receptor by increased ligand affinity. J Biol Chem (1998) 0.83
Several dehydrogenases and kinases compete for endocytosis from plasma by rat tissues. Biochem J (1985) 0.83
In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology (1982) 0.83
Effect of intraperitoneal administration of granulocyte/macrophage-colony-stimulating factor in rats on omental milky-spot composition and tumoricidal activity in vivo and in vitro. Cancer Immunol Immunother (1996) 0.83
Sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of stavudine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.82
Modulation of the production of a parathyroid hormone-like protein in human squamous carcinoma cell lines by interaction with fibroblasts. Cancer Res (1990) 0.82
The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer (1991) 0.82
Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler Thromb Vasc Biol (1998) 0.82
Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants. J Bone Miner Res (1991) 0.81
Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Calcif Tissue Int (1983) 0.81
Virus-encoded G-protein-coupled receptors: constitutively active (dys)regulators of cell function and their potential as drug target. Ernst Schering Found Symp Proc (2006) 0.81
Combined diphosphonate and calcitonin therapy for Paget's disease of bone. Calcif Tissue Res (1976) 0.80
Polysaccharide from coccoliths (CaCO3 biomineral). Influence on crystallization of calcium oxalate monohydrate. Eur J Biochem (1986) 0.80
Effects of long-term porcine calcitonin administration in patients with Paget's disease or osteoporosis. Calcif Tissue Res (1970) 0.80
Mouse P19 embryonal carcinoma cells express functional histamine H1-receptors. Biochem Biophys Res Commun (1993) 0.79
Familial benign hypercalcaemia (FBH; McK. No. 14598, 1983): linkage studies in a large Dutch family. Hum Genet (1984) 0.79
Iliac bone marrow trephine biopsy: some remarks on the technique. Neth J Med (1978) 0.79
Site-directed mutagenesis of the histamine H1-receptor reveals a selective interaction of asparagine207 with subclasses of H1-receptor agonists. Biochem Biophys Res Commun (1994) 0.79